Loading...
XSTOVICO
Market cap163mUSD
Dec 23, Last price  
7.71SEK
1D
-1.91%
1Q
10.14%
Jan 2017
-52.17%
IPO
46.16%
Name

Vicore Pharma Holding AB

Chart & Performance

D1W1MN
XSTO:VICO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.37%
Rev. gr., 5y
-11.73%
Revenues
0k
3,3143,305,0001,571,000840,000852,000932,000508,00000000
Net income
-311m
L+7.81%
-3,158-1,603,00013,687,000-4,570,000-6,652,000-12,855,000-21,681,000-93,084,000-146,862,000-296,481,000-288,422,000-310,942,000
CFO
-250m
L-16.78%
-1,669-1,793,000-2,825,000-3,682,000-7,251,000-7,705,000-33,036,000-86,999,000-119,935,000-265,171,000-299,919,000-249,583,000
Earnings
Feb 27, 2025

Profile

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
URL
https://vicorepharma.com/
IPO date
Dec 10, 2015
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
320,889
291,106
297,018
Unusual Expense (Income)
NOPBT
(320,889)
(291,106)
(297,018)
NOPBT Margin
Operating Taxes
(384)
(384)
(254)
Tax Rate
NOPAT
(320,505)
(290,722)
(296,764)
Net income
(310,942)
7.81%
(288,422)
-2.72%
(296,481)
101.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
500,406
187,292
336,000
BB yield
-36.55%
-14.49%
-34.64%
Debt
Debt current
65
Long-term debt
65
320
Deferred revenue
320
Other long-term liabilities
898
1,600
600
Net debt
(482,766)
(261,678)
(299,288)
Cash flow
Cash from operating activities
(249,583)
(299,919)
(265,171)
CAPEX
(3,000)
Cash from investing activities
(144,455)
74,000
(7,000)
Cash from financing activities
470,855
187,040
318,183
FCF
(320,476)
(290,692)
(296,735)
Balance
Cash
482,766
261,743
371,199
Long term investments
(71,591)
Excess cash
482,766
261,743
299,608
Stockholders' equity
(1,218,401)
(921,728)
(638,350)
Invested Capital
1,674,688
1,211,716
1,022,251
ROIC
ROCE
EV
Common stock shares outstanding
96,559
72,214
69,678
Price
14.18
-20.78%
17.90
28.59%
13.92
-55.81%
Market cap
1,369,204
5.92%
1,292,638
33.27%
969,924
-43.24%
EV
886,438
1,030,961
670,636
EBITDA
(317,596)
(287,494)
(293,420)
EV/EBITDA
Interest
358
8
11
Interest/NOPBT